Investigating how leukemia inhibitory factor affects colorectal cancer
The role of leukemia inhibitory factor in colorectal cancer
This study is looking at how a protein called leukemia inhibitory factor (LIF) affects colorectal cancer and its connection to another important protein, p53, to find new ways to treat this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11061797 on NIH RePORTER |
What this research studies
This research explores the role of leukemia inhibitory factor (LIF) in colorectal cancer, particularly its complex relationship with the tumor suppressor protein p53. The study aims to understand how LIF contributes to the initiation and progression of colorectal cancer by influencing cancer stem cells and their metabolic processes. By examining the mechanisms through which LIF affects tumor-initiating cells, the research seeks to identify potential therapeutic strategies for targeting colorectal cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with colorectal cancer, particularly those with aggressive forms of the disease.
Not a fit: Patients with non-cancerous conditions or those with colorectal cancer that is not influenced by LIF may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target colorectal cancer stem cells, improving outcomes for patients.
How similar studies have performed: Other research has shown promising results in targeting cancer stem cells, suggesting that this approach may be effective in colorectal cancer as well.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Hu, Wenwei — Rutgers Biomedical and Health Sciences
- Study coordinator: Hu, Wenwei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.